Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNLIP | P16233 | 9/20 | 0.72 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.65 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30515438 | 1.00 | PNLIP (0.72) | PNLIPPTPN1PTPN2POLBMAPT | |
| SCHEMBL16259431 | 1.00 | PNLIP (0.72) | PNLIPPTPN1PTPN2POLBMAPT | |
| SCHEMBL14356951 | 0.86 | PNLIP (0.62) | PNLIPPTPN1PTPN2POLBMAPT | |
| Labdadienedial SCHEMBL16260939 | 0.84 | PNLIP (1.00) | PNLIPPTPN1PTPN2POLBMAPT | |
| Labdadienedial SCHEMBL14023290 | 0.84 | PNLIP (1.00) | PNLIPPTPN1PTPN2POLBMAPT | |
| Labdadienedial SCHEMBL29390865 | 0.84 | PNLIP (1.00) | PNLIPPTPN1PTPN2POLBMAPT | |
| SCHEMBL25397921 | 0.82 | PNLIP (0.58) | PNLIPPTPN1PTPN2POLBMAPT | |
| SCHEMBL30585231 | 0.82 | PNLIP (0.58) | PNLIPPTPN1PTPN2POLBMAPT | |
| SCHEMBL25395046 | 0.82 | PNLIP (0.58) | PNLIPPTPN1PTPN2POLBMAPT | |
| SCHEMBL25435569 | 0.82 | PNLIP (0.58) | PNLIPPTPN1PTPN2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220364016-A1 | PERFUME OIL MIXTURE | SYMRISE AG (DE) | 2022-11-17 | — | — | US | claimed |
| EP-4025675-A1 | A PERFUME OIL MIXTURE | Symrise AG (DE) | 2022-07-13 | — | — | EP | claimed |
| CN-114364773-A | Aromatic oil mixture | 西姆莱斯股份公司 | 2022-04-15 | — | — | CN | claimed |
| EP-4735024-A1 | MODIFIED HUMAN LYMPHOCYTES CONTAINING AND EXPRESSING POSITIVE REGULATORS OF AUTOPHAGY | Julius-Maximilians-Universität Würzburg (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-20260108606-A1 | TREATMENT OF AUTOIMMUNE DISEASES HAVING A PATHOGENIC T CELL STATE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4025675-B1 | A PERFUME OIL MIXTURE | SYMRISE AG (DE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4687810-A1 | PREPARATIONS COMPRISING HYDROXY PINACOLONE RETINOATE | Symrise AG (DE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025226652-A9 | NUCLEIC ACID SEQUENCES FOR REDUCING CHEMORESISTANCE AND TREATING DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025226652-A2 | NUCLEIC ACID SEQUENCES FOR REDUCING CHEMORESISTANCE AND TREATING DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12421474-B2 | Perfume oil mixture | SYMRISE AG (DE) | 2025-09-23 | — | — | US | disclosed |
| EP-3684898-B1 | METHOD FOR PRODUCING AN ACTIVE SUBSTANCE WAFER | SYMRISE AG (DE) | 2025-04-30 | — | — | EP | disclosed |
| EP-3185868-B1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INST FOR BIOLOGICAL STUDI (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20150197480-A9 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR MODULATORS AND USES THEREOF IN REGULATING BLOOD GLUCOSE LEVELS | ACADEMIA SINICA (TW) | 2015-07-16 | — | — | US | disclosed |
| US-20150197480-A9 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR MODULATORS AND USES THEREOF IN REGULATING BLOOD GLUCOSE LEVELS | ACADEMIA SINICA (TW) | 2015-07-16 | — | — | US | disclosed |
| WO-2014193832-A2 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR MODULATORS AND USES THEREOF IN REGULATING BLOOD GLUCOSE LEVELS | ACADEMIA SINICA (TW) | 2014-12-04 | — | — | WO | disclosed |
| US-20140350100-A1 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR MODULATORS AND USES THEREOF IN REGULATING BLOOD GLUCOSE LEVELS | ACADEMIA SINICA (TW) | 2014-11-27 | — | — | US | disclosed |
| US-20140350100-A1 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR MODULATORS AND USES THEREOF IN REGULATING BLOOD GLUCOSE LEVELS | ACADEMIA SINICA (TW) | 2014-11-27 | — | — | US | disclosed |
| EP-0212254-B1 | PROCESS FOR THE PREPARATION OF OXYGENATED DECALINE COMPOUNDS | FIRMENICH SA (CH) | 1991-10-09 | — | — | EP | disclosed |
| US-4701543-A | Process for the preparation of oxygenated decaline derivatives | FIRMENICH S.A. (CH) | 1987-10-20 | — | — | US | disclosed |
| EP-0212254-A2 | Process for the preparation of oxygenated decaline compounds | FIRMENICH SA (CH) | 1987-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350100-A1 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR MODULATORS AND USES THEREOF IN REGULATING BLOOD GLUCOSE LEVELS | GLP1R, GIPR, GCGR | PNLIP 61/4885PTPN1 238/4885PTPN2 350/4885 |
| US-20260108606-A1 | TREATMENT OF AUTOIMMUNE DISEASES HAVING A PATHOGENIC T CELL STATE | IL17A, CD4, PMP22 | PNLIP 1825/4885PTPN1 2540/4885PTPN2 2212/4885 |
| US-20150197480-A9 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR MODULATORS AND USES THEREOF IN REGULATING BLOOD GLUCOSE LEVELS | GLP1R, GIPR, GCGR | PNLIP 61/4885PTPN1 238/4885PTPN2 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.